Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial (Q39344567)

11 September 2017

title

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial (English)

1 reference

amyotrophic lateral sclerosis

11 September 2017

main subject

phase III clinical trial

0 references

placebo

0 references

0 references

author

Carolyn A. Young

15

1 reference

11 September 2017

Orla Hardiman

7

0 references

Leonard H van den Berg

2

object named as

Leonard H van den Berg

1 reference

11 September 2017

6

Albert Ludolph

1 reference

11 September 2017

4

Hiroshi Mitsumoto

1 reference

11 September 2017

1

Merit E Cudkowicz

1 reference

ORCID Public Data File 2021

11 September 2017

1 reference

Jeremy M Shefner

3

object named as

Jeremy M Shefner

1 reference

11 September 2017

Jesus S Mora

5

1 reference

11 September 2017

Michael E Bozik

8

1 reference

11 September 2017

Evan W Ingersoll

9

1 reference

11 September 2017

Donald Archibald

10

1 reference

11 September 2017

Adam L Meyers

11

1 reference

11 September 2017

Yingwen Dong

12

1 reference

11 September 2017

Wildon R Farwell

13

1 reference

11 September 2017

Douglas A Kerr

14

1 reference

11 September 2017

publication date

23 September 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

12

1 reference

11 September 2017

issue

11

1 reference

11 September 2017

page(s)

1059-1067

1 reference

Amyotrophic lateral sclerosis

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Mitochondria: a therapeutic target in neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Combining mortality and longitudinal measures in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Progression in ALS is not linear but is curvilinear.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Lithium delays progression of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

ALS drug development: reflections from the past and a way forward

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Designing clinical trials in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Toward more efficient clinical trials for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

Controversies and priorities in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970221-7

7 January 2021

10.1016/S1474-4422(13)70221-7

Identifiers

DOI

1 reference

11 September 2017

1 reference